| Axitinib Looks Good in Head-to-Head Renal Cancer Trial - MedPage Today |
|
|
MedPage Today In what was described as the first phase III head-to-head comparison of targeted agents in advanced renal cell carcinoma, patients getting axitinib had a median progression-free survival of 6.7 months, according to Brian Rini, MD, of the Cleveland |